CN112851515A - 一种清热解毒的绿原酸衍生物及其制备方法 - Google Patents
一种清热解毒的绿原酸衍生物及其制备方法 Download PDFInfo
- Publication number
- CN112851515A CN112851515A CN202110070180.0A CN202110070180A CN112851515A CN 112851515 A CN112851515 A CN 112851515A CN 202110070180 A CN202110070180 A CN 202110070180A CN 112851515 A CN112851515 A CN 112851515A
- Authority
- CN
- China
- Prior art keywords
- chlorogenic acid
- preparation
- stirring
- clearing away
- away heat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical class O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000463 material Substances 0.000 title claims abstract description 11
- 231100000331 toxic Toxicity 0.000 title claims abstract description 11
- 230000002588 toxic effect Effects 0.000 title claims abstract description 11
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 25
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 25
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 25
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 25
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 25
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 25
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 25
- 238000006243 chemical reaction Methods 0.000 claims abstract description 20
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 claims abstract description 16
- ZJIOBDJEKDUUCI-UHFFFAOYSA-N 3,5-dimethylbenzoyl chloride Chemical compound CC1=CC(C)=CC(C(Cl)=O)=C1 ZJIOBDJEKDUUCI-UHFFFAOYSA-N 0.000 claims abstract description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000741 silica gel Substances 0.000 claims abstract description 8
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 8
- 239000005051 trimethylchlorosilane Substances 0.000 claims abstract description 8
- 239000003513 alkali Substances 0.000 claims abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 238000004809 thin layer chromatography Methods 0.000 claims description 10
- 239000003208 petroleum Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 239000012044 organic layer Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 229960001701 chloroform Drugs 0.000 claims description 2
- KVNYFPKFSJIPBJ-UHFFFAOYSA-N ortho-diethylbenzene Natural products CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims 1
- 239000012266 salt solution Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 8
- 241000894006 Bacteria Species 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 230000001476 alcoholic effect Effects 0.000 abstract 1
- 239000012043 crude product Substances 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- 239000008923 Qingkailing Substances 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 206010069767 H1N1 influenza Diseases 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 208000037386 Typhoid Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229940117173 croton oil Drugs 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 201000010740 swine influenza Diseases 0.000 description 4
- 201000008297 typhoid fever Diseases 0.000 description 4
- 206010014025 Ear swelling Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 101100062776 Arabidopsis thaliana DCL3 gene Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000031636 Body Temperature Changes Diseases 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000002802 antimicrobial activity assay Methods 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 210000004191 axillary artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- -1 phenylpropanoid compound Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/14—Preparation of carboxylic acid esters from carboxylic acid halides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/56—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种清热解毒的绿原酸衍生物及其制备方法,本发明属于化学药物合成制备技术领域;所述衍生物的制备方法包括:在无水环境中,碱作用下,绿原酸与三甲基氯硅烷发生醇羟基保护反应,再依次与3,5‑二甲基苯甲酰氯反应,再通过硅胶柱再将粗产物进一步纯化分离,得到绿原酸衍生物;本发明对绿原酸结构改造,寻找到了结构更新颖、活性更强的化合物,并且在清热解毒、抗菌消炎等功效上具有显著效果;本发明提供的制备方法原料简单易得,反应条件温和,后处理简单方便,对环境友好,适合于工业化生产。
Description
技术领域
本发明属于化学药物合成制备技术领域,涉及一种清热解毒的绿原酸衍生物及其制备方法。
背景技术
绿原酸是植物体内在有氧呼吸过程中经莽草酸途径产生的一种苯丙素类化合物,自20世纪50年代首次从苹果中提取成功就一直受到学者们的高度关注。研究表明绿原酸具有清热解毒的功效,常被用在清热解毒的中药类制剂中。但是绿原酸分子中存在苯酚结构,苯酚常置于空气中容易发生氧化,使绿原酸的结构发生改变,变得不稳定,影响其生物活性,因此需要对绿原酸结构进行修饰,获得结构更加稳定的绿原酸衍生物,同时还能拥有更好的生物活性。
发明内容
为了解决上述技术问题,本发明提供了一种清热解毒的绿原酸衍生物,其衍生物具有式(I)分子结构:
本发明的另一个目的在于提供清热解毒的绿原酸衍生物的制备方法,包括如下步骤:
在氮气保护下,室温下将绿原酸溶解于无水有机溶剂中,加入无水碱,再加入三甲基氯硅烷,室温下搅拌反应2~3h,TLC检测反应结束;在反应液中加入3,5-二甲基苯甲酰氯,搅拌溶解,升高温度至80~110℃,TLC检测反应结束,加入盐酸溶液,搅拌3~5h,用饱和食盐水洗涤,有机层用无水硫酸钠干燥,减压蒸馏除去溶剂,残留物硅胶柱洗脱层析得最终产物;
所述绿原酸与三甲基氯硅烷的摩尔比为1:(1.0~4.5);
所述绿原酸与3,5-二甲基苯酰氯的摩尔比为1:(1.5~3.5);
所述碱为三乙胺、乙二胺、氢氧化钠、碳酸钠、醋酸钠或碳酸钾;
所述有机溶剂为二氯甲烷、三氯甲烷、四氢呋喃、丙酮、乙腈或乙醚、苯或甲苯;
所述硅胶柱洗脱液为石油醚与二氯甲烷的混合液,其中石油醚与二氯甲烷的体积比为(2~7):1。
根据上述制备方法的一种优选,包括如下步骤:
在氮气保护下,室温下将15g绿原酸溶解于无水120mL二氯甲烷中,加入无水三乙胺,再加入13.8g三甲基氯硅烷,室温下搅拌反应3h,TLC检测反应结束;在反应液中加入17.8g 3,5-二甲基苯甲酰氯,搅拌溶解,升高温度至110℃,TLC检测反应结束,加入盐酸溶液,搅拌3h,用饱和食盐水洗涤,有机层用无水硫酸钠干燥,减压蒸馏除去溶剂,残留物以体积比为2:1的石油醚与二氯甲烷的混合液为洗脱液,将残留物经硅胶柱洗脱层析得最终产物。
现有技术相比,本发明的有益效果是:
本发明采用天然植物提取物绿原酸,对其结构改性,获得一种具有酰胺键的绿原酸衍生物;病理实验表明,绿原酸衍生物对大肠杆菌、表皮葡萄球菌表现出较好的抑制活性,尤其对大肠杆菌抑制活性更加显著,比单独使用的绿原酸的抑制效果更好;对H1N1流感病毒业具有显著的抑制作用;对抑制巴豆油致小鼠耳肿胀,其抑制效果与清开灵注射液相当;以及对伤寒、副伤寒甲乙三联菌苗所致家兔发热具有降低作用。总之,本发明的绿原酸衍生物具有发展为清热解毒药物的潜力。
附图说明
图1:实施例1的清热解毒的绿原酸衍生物核磁共振氢谱图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,下面结合具体实施方式对本发明作进一步的详细描述,但不应将此理解为本发明上述主题的范围仅限于下述实施例。
实施例1
在氮气保护下,室温下将15g绿原酸溶解于无水120mL二氯甲烷中,加入无水三乙胺,再加入13.8g三甲基氯硅烷,室温下搅拌反应3h,TLC检测反应结束;在反应液中加入17.8g 3,5-二甲基苯甲酰氯,搅拌溶解,升高温度至110℃,TLC检测反应结束,加入盐酸溶液,搅拌3h,用饱和食盐水洗涤,有机层用无水硫酸钠干燥,减压蒸馏除去溶剂,残留物以体积比为2:1的石油醚与二氯甲烷的混合液为洗脱液,将残留物经硅胶柱洗脱层析得最终产物。产率为80.33%。
核磁共振氢谱检测:
将样品放入样品管中,用注射器取0.5mLCDCL3(氘代氯仿)注入样品管,使样品充分溶解。要求样品与试剂充分混合,溶液澄清、透明、无悬浮物或其他杂质,经核磁共振鉴定,得到核磁共振氢谱图,结果见如图1。
实施例2本发明化合物对清热解毒的药效学试验
1.本发明药物的体外抗菌活性实验
供试菌种:金黄色葡萄球菌(a)、大肠杆菌(b)、枯草芽孢杆菌(c)、表皮葡萄球菌(d)、白色念珠球菌(e)。
将本发明的绿原酸衍生物溶解在无水乙醇中,用胰蛋白胨大豆肉汤培养液稀释至1000μg/mL,继续用培养液稀释使药物的浓度从256~0.25μg/mL,获得实验溶液;再配制浓度范围为256~0.25μg/mL的清开灵注射液作为阳性对照组(对照组1);同样的方法配制绿原酸作为对照组2。在96孔板上每孔加入浓度范围为256~0.25μg/mL的药液和100μL的菌液,最终药物的浓度为5×104CFU,以胰蛋白胨大豆肉汤培养基加菌液作为阴性对照(TSB培养基、菌液各100μL),以不加菌液的TSB肉汤培养基为空白对照(TSB培养基200μL),将96孔板密封后置于37℃恒温培箱中,孵育20小时。测定各孔625nm处的吸光度光度值,与空白对照组OD625值一致的孔视为细菌无明显生长。细菌无明显生长的药物最低浓度为本发明化合物的最小抑菌浓度MIC。
表1本发明化合物的体外抗菌活性测试
由表1数据表明,绿原酸衍生物对大肠杆菌、表皮葡萄球菌表现出较好的抑制活性,尤其对大肠杆菌抑制活性更加显著,比单独使用的绿原酸的抑制效果更好。
2.本发明化合物对感染H1N1流感病毒小鼠肺指数影响
选取昆明小鼠若干,随机分组,分别为正常对照组(对照组1)、模型对照组(对照组2)、清开灵注射液(对照组3)、绿原酸组(对照组4)、实验组。小鼠每天灌喂给药1次,各组动物给药2天后,小鼠用乙醚轻度麻醉,以15个LD50病毒液滴鼻感染,每只小鼠0.5mL,小鼠苏醒后继续给药4天。正常对照组和病毒对照组给与等体积生理盐水。第5天称量体重,腋下动脉放血处死后取出鼠肺,计算肺指数和抑制率,肺指数值越大,表示肺炎越严重,结果见表2。
肺指数抑制率=(病毒对照组肺指数均值-实验组肺指数均值)/病毒对照组肺指数均值×100%。
肺指数=肺湿重(g)/体重
表2本发明化合物对感染H1N1流感病毒小鼠肺指数影响
组别 | 剂量(g/kg) | 肺指数值 | 抑制率(%) |
对照组1 | - | 0.79±0.07 | - |
对照组2 | - | 2.47±0.21 | - |
对照组3 | 0.09 | 1.12±0.15 | 46.2 |
对照组4 | 30.0 | 1.32±0.18 | 32.1 |
实验组 | 30.0 | 1.20±0.21 | 40.3 |
由表2数据表明,本发明化合物能有效降低肺指数,肺指数抑制率为40.3%,高于单独作用的绿原酸抑制率(32.1%),由此说明,本发明的绿原酸衍生物对H1N1流感病毒具有显著的抑制作用。
3.本发明化合物的抗炎作用实验
选取健康的雄性昆明小鼠,随机分组为:模型组(对照组1)、清开灵注射液组(对照组2)、绿原酸组(对照组3)、实验组。每组动物每天给药一次,模型组灌喂等体积的蒸馏水,其他各组灌喂相对应的药物,连续灌喂三天,于末次给药1h后,在每只动物左耳涂抹巴豆油0.02mL,右耳不涂作为正常耳,致炎4h后处死,剪下两只耳朵,用直径0.8cm打孔器在耳同一部位打下耳片,分别称取两片耳重量,以重量差值作为肿胀程度。实验结果见表3。
肿胀抑制率%=(模型组左右耳片重量差-给药组左右耳片重量差)/模型组左右耳片重量差×100%
表3本发明化合物对巴豆油致小鼠耳肿胀的影响
组别 | 剂量(g/kg) | 肿胀度 | 肿胀抑制率(%) |
对照组1 | - | 35.39±2.72 | - |
对照组2 | 15.0 | 23.16±3.04 | 50.59 |
对照组3 | 30.0 | 30.48±2.37 | 27.51 |
实验组 | 30.0 | 25.61±2.26 | 45.77 |
由表3数据表明,与模型组相比,本发明的绿原酸衍生物能显著抑制巴豆油致小鼠耳肿胀,其抑制效果与清开灵注射液相当,且优于单独使用时的绿原酸的抑制效果。
4.本发明化合物的解热作用实验
测试本发明药物对伤寒、副伤寒甲乙三联菌苗所致家兔发热模型的影响。选取健康的家兔,随机分组。连续测3次肛温,每次3min,间隔1h,将3次结果的平均值作为基础体温,然后在兔子耳朵静脉注射伤寒、副伤寒甲乙三联菌苗1mL/kg,待肛温升高0.5℃时灌喂给药。实验组灌喂给药绿原酸衍生物15g/kg,模型组(对照组1)灌喂给予等量的蒸馏水,阳性对照组(对照组2)清开灵注射液,绿原酸组(对照组3)灌喂给予30g/kg绿原酸,每隔1h测温一次,连续6h。计算各组动物在给药后不同时间内的体温变化,实验结果见表4。
表4本发明化合物的解热作用影响
由表4数据表明,与模型对照组相比,三种药物均能降低感染伤寒、副伤寒甲、乙三联菌苗后家兔的体温,其中绿原酸衍生物与清开灵注射液的效果相当,且都远优于单独作用的绿原酸降温效果。
Claims (3)
2.一种清热解毒的绿原酸衍生物的制备方法,其特征在于,包括如下步骤:
在氮气保护下,室温下将绿原酸溶解于无水有机溶剂中,加入无水碱,再加入三甲基氯硅烷,室温下搅拌反应2~3h,TLC检测反应结束;在反应液中加入3,5-二甲基苯甲酰氯,搅拌溶解,升高温度至80~110℃,TLC检测反应结束,加入盐酸溶液,搅拌3~5h,用饱和食盐水洗涤,有机层用无水硫酸钠干燥,减压蒸蒸除去溶剂,残留物硅胶柱洗脱层析得最终产物;
所述绿原酸与三甲基氯硅烷的摩尔比为1:(1.0~4.5);
所述绿原酸与3,5-二甲基苯酰氯的摩尔比为1:(1.5~3.5);
所述碱为三乙胺、乙二胺、氢氧化钠、碳酸钠、醋酸钠或碳酸钾;
所述有机溶剂为二氯甲烷、三氯甲烷、四氢呋喃、丙酮、乙腈或乙醚、苯或甲苯;
所述硅胶柱洗脱液为石油醚与二氯甲烷的混合液,其中石油醚与二氯甲烷的体积比为(2~7):1。
3.根据权利要求2所述清热解毒的绿原酸衍生物的制备方法,其特征在于,包括如下步骤:
在氮气保护下,室温下将15g绿原酸溶解于无水120mL二氯甲烷中,加入无水三乙胺,再加入13.8g三甲基氯硅烷,室温下搅拌反应3h,TLC检测反应结束;在反应液中加入17.8g3,5-二甲基苯甲酰氯,搅拌溶解,升高温度至110℃,TLC检测反应结束,加入盐酸溶液,搅拌3h,用饱和食盐水洗涤,有机层用无水硫酸钠干燥,减压蒸馏除去溶剂,残留物以体积比为2:1的石油醚与二氯甲烷的混合液为洗脱液,将残留物经硅胶柱洗脱层析得最终产物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110070180.0A CN112851515A (zh) | 2021-01-19 | 2021-01-19 | 一种清热解毒的绿原酸衍生物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110070180.0A CN112851515A (zh) | 2021-01-19 | 2021-01-19 | 一种清热解毒的绿原酸衍生物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112851515A true CN112851515A (zh) | 2021-05-28 |
Family
ID=76007400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110070180.0A Withdrawn CN112851515A (zh) | 2021-01-19 | 2021-01-19 | 一种清热解毒的绿原酸衍生物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112851515A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112724142A (zh) * | 2021-01-19 | 2021-04-30 | 籍建亚 | 一种抗抑郁的茶碱衍生物及其制备方法 |
CN112851576A (zh) * | 2021-01-19 | 2021-05-28 | 谢天龙 | 一种清热解毒的绿原酸衍生物及其制备方法 |
CN112876469A (zh) * | 2021-01-19 | 2021-06-01 | 籍建亚 | 一种镇咳化痰羽扇豆碱衍生物及其制备方法 |
CN113173895A (zh) * | 2021-05-12 | 2021-07-27 | 籍建亚 | 一种抗流感病毒感染的穿心莲内酯衍生物及其制备方法 |
CN113387864A (zh) * | 2021-06-15 | 2021-09-14 | 广西大学 | 一种s-吲哚苯甲酰胺衍生物及其制备方法与应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112851576A (zh) * | 2021-01-19 | 2021-05-28 | 谢天龙 | 一种清热解毒的绿原酸衍生物及其制备方法 |
-
2021
- 2021-01-19 CN CN202110070180.0A patent/CN112851515A/zh not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112851576A (zh) * | 2021-01-19 | 2021-05-28 | 谢天龙 | 一种清热解毒的绿原酸衍生物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
黄美娥: "紫花地丁中绿原酸紫花地丁中绿原酸的紫花地丁中绿原酸的提取与纯化技术研究提取与纯化技术研究的提取与纯化技术研究", 《中国优秀博硕士学位论文全文数据库(硕士)农业科技辑》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112724142A (zh) * | 2021-01-19 | 2021-04-30 | 籍建亚 | 一种抗抑郁的茶碱衍生物及其制备方法 |
CN112851576A (zh) * | 2021-01-19 | 2021-05-28 | 谢天龙 | 一种清热解毒的绿原酸衍生物及其制备方法 |
CN112876469A (zh) * | 2021-01-19 | 2021-06-01 | 籍建亚 | 一种镇咳化痰羽扇豆碱衍生物及其制备方法 |
CN112876469B (zh) * | 2021-01-19 | 2022-08-26 | 广东博卓医药科技有限公司 | 一种镇咳化痰羽扇豆碱衍生物及其制备方法 |
CN113173895A (zh) * | 2021-05-12 | 2021-07-27 | 籍建亚 | 一种抗流感病毒感染的穿心莲内酯衍生物及其制备方法 |
CN113387864A (zh) * | 2021-06-15 | 2021-09-14 | 广西大学 | 一种s-吲哚苯甲酰胺衍生物及其制备方法与应用 |
CN113387864B (zh) * | 2021-06-15 | 2023-08-01 | 广西大学 | 一种s-吲哚苯甲酰胺衍生物及其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112851515A (zh) | 一种清热解毒的绿原酸衍生物及其制备方法 | |
CN112851576A (zh) | 一种清热解毒的绿原酸衍生物及其制备方法 | |
CN112745280A (zh) | 一种清热解毒的绿原酸衍生物及其制备方法 | |
CN103333148B (zh) | 3,3′-(3,4-二氯苯亚甲基)-双-4-羟基香豆素及其在制备抗多重耐药细菌药物中的应用 | |
CN113861008B (zh) | 大苞松香二萜及其制备方法和作为制备预防或/和治疗炎症的抗炎、抗菌药物中的应用 | |
CN113831245B (zh) | 大苞荆芥提取物中的二萜及其制备方法和应用 | |
CN113072611A (zh) | 一种甘草次酸修饰的多吡啶钌配合物及其制备方法和应用 | |
CN100494193C (zh) | 8-辛基小檗碱盐酸盐、合成方法及应用 | |
CN102603524A (zh) | 一种醌类衍生物及其制备方法与作为抗菌剂的应用 | |
CN110615742B (zh) | 厚朴酚衍生物及其制备方法与应用 | |
CN112851512A (zh) | 一种清热解毒的绿原酸衍生物及其制备方法 | |
CN110551072A (zh) | 具有抑制dna拓扑异构酶活性的喹噁啉-n1,n4-二氧化物衍生物、制备方法及应用 | |
CN110664795A (zh) | 水溶性组合物及其制备方法与应用 | |
CN114044734A (zh) | 松香烷二萜及其制备方法和应用 | |
CN108503521B (zh) | 愈创木烷型倍半萜a及其制备方法和作为制备预防肿瘤和抗肿瘤药物的应用 | |
US3843784A (en) | Antibiotics a201a and a201b and process for the production thereof | |
CN102659547B (zh) | 一种蛇孢假壳素类二倍半萜化合物及其制备和应用 | |
CN113861126B (zh) | 高度氧化二萜及其制备方法和作为制备预防或/和治疗炎症的抗炎、抗菌药物中的应用 | |
CN114891010A (zh) | 一种白鲜皮中白鲜碱类化合物的提取纯化方法及其在抗mrsa的应用 | |
DE2040141C3 (de) | Dipeptide und Verfahren zu ihrer Herstellung | |
CN112279841A (zh) | 一种抗病毒穿心莲内酯衍生物及其制备方法 | |
CN110452278B (zh) | 臭七次生代谢物及其制备方法与其在制药中的应用 | |
CN102051394A (zh) | 一种硫代二酮哌嗪类化合物制备方法及其应用 | |
CN107746422B (zh) | 麦角甾-7,22-二烯-3-酮缩氨硫腙及其制备方法和在制备抗菌药物中的应用 | |
Grunberg et al. | Studies on the in vitro and in vivo chemotherapeutic properties of the antibiotic myxin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210528 |
|
WW01 | Invention patent application withdrawn after publication |